◀ Back to NOS1

EDN1 — NOS1

Text-mined interactions from Literome

Marsen et al., Pflugers Arch 1999 : Tyrosine-kinase dependent regulation of the nitric oxide synthase gene by endothelin-1 in human endothelial cells
Barton et al., J Am Soc Nephrol 2000 (Glomerulosclerosis, Focal Segmental...) : Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension : mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and Glomerulosclerosis
Zhang et al., Can J Physiol Pharmacol 2000 : The current project sought to study the effect of the NOS inhibitor Nomega-nitro-L-arginine methyl ester ( L-NAME, 10 microg x min ( -1 ), sc for 7 days ) on plasma volume, plasma atrial natriuretic factor ( ANF ), plasma endothelin-1 (ET) , and plasma renin activity (PRA) during gestation in conscious rats
Zhan et al., Sheng li ke xue jin zhan [Progress in physiology] 2000 (Cardiomyopathy, Hypertrophic) : Angiotensin II ( AII ), endothelin-1 (ET-1) and norepinephrine ( NE ) can inhibit NOS activity and NO production, and induce hypertrophic response in cultured neonatal rat cardiomyocytes ; these effects of AII, ET-1 and NE are mediated respectively by AII receptor, ETA receptor and alpha 1-adrenergic receptor ; these effects of AII and ET-1 are mediated by PTX-sensitive G protein, while the effects of NE are mediated by PTX-insensitive G protein
Schwerte et al., J Exp Biol 2002 : We used novel digital contrasting methods to measure the effects of endothelin-1 ( ET-1, 10 ( -6 ) to 10 ( -8 ) mol l ( -1 ) ), the nitric-oxide releasing agent sodium nitroprusside ( SNP, 10 ( -2 ) mol l ( -1 ) ) and N ( omega ) -nitro-L-arginine methyl ester hydrochloride ( L-NAME, 10 ( -4 ) mol l ( -1 ) ), a non-selective inhibitor of nitric oxide synthase , on the diameter of tiny arteries and veins of the head in anaesthetized Xenopus laevis tadpoles ( stage NF 50-53 )
Liu et al., J Biol Chem 2003 : Endothelin-1 activates endothelial cell nitric-oxide synthase via heterotrimeric G-protein betagamma subunit signaling to protein jinase B/Akt
Luo et al., Am J Physiol Gastrointest Liver Physiol 2004 (Hepatopulmonary Syndrome...) : Both increased hepatic endothelin-1 (ET-1) production and pulmonary vascular ET ( B ) receptor expression with stimulation of endothelial nitric oxide synthase and TNF-alpha mediated inducible nitric oxide synthase and heme oxygenase-1 expression in pulmonary intravascular macrophages occur
Verma et al., J Surg Res 2004 (Anoxia) : In some experiments, the effects of endothelin ( ET ) receptor blockade ( with bosentan ) and nitric oxide synthase (NOS) inhibition ( with L-NAME ) on pravastatin mediated cardioprotection were evaluated
Ohlstein et al., J Neurosurg 1992 : An l-arginine analog inhibitor of nitric oxide synthase , L-NG-monomethyl arginine ( L-NMMA, 200 microM ), did not significantly affect basal immunoreactive endothelin levels
Boiti et al., Biol Reprod 2007 : EDN1 decreased ( P < /= 0.01 ) progesterone release and increased ( P < /= 0.01 ) PGF2alpha secretion and NOS activity via the PLC/PKC pathway in Day-9 CL, but not in Day-4 CL, cultured in vitro
Novella et al., Eur J Cardiothorac Surg 2007 (Cardiovascular Diseases) : No change in the AVP response was produced by endothelium removal, exposure to the NO precursor ( 3 x 10 ( -4 ) M L-arginine ), inhibition of nitric oxide ( NO ) synthase ( 3 x 10 ( -5 ) M L-NAME ) or soluble guanylate cyclase ( 3 x 10 ( -6 ) M 1H- [ 1,2,4 ] oxadiazol [ 4,3,-alpha ] quinoxalin-1-one ( ODQ ) ), removal of the superoxide anion ( 100 U/ml superoxide dismutase ( SOD ) plus 1200 U/ml catalase ) or hydroxyl radical ( 10 ( -4 ) M deferoxamine ), or specific alpha1 - ( 10 ( -6 ) M prazosin ) or endothelin ( 10 ( -5 ) M bosentan ) receptor antagonism
Oku et al., Exp Eye Res 2008 : Endothelin-1 (ET-1) causes death of retinal neurons through activation of nitric oxide synthase (NOS) and production of superoxide anion
Hsu et al., Am J Physiol Lung Cell Mol Physiol 2010 : We have previously demonstrated that this potent vasoconstricting response is due, in part, to an endothelin-1 (ET-1) mediated decrease in nitric oxide synthase (NOS) activity
Kwok et al., Am J Physiol Gastrointest Liver Physiol 2009 : Caveolin-1 mediates endotoxin inhibition of endothelin-1 induced endothelial nitric oxide synthase activity in liver sinusoidal endothelial cells
Franchi et al., Proc Natl Acad Sci U S A 1994 : Cholinergic stimulation of vascular endothelin activates NO synthase (NOS) , leading to generation of NO from arginine
Fujita et al., Eur J Pharmacol 1995 (Disease Models, Animal...) : We examined the effect of long-term nitric oxide ( NO ) synthase inhibition on vascular and renal endothelin-1 levels and evaluated the antihypertensive effect of endothelin ETA receptor antagonist FR139317 ( ( R ) 2 ( - ) [ ( R ) -2 ( - ) [ ( S ) -2 ( - ) [ [ 1- ( hexahydro-1H-azepinyl ) ] - carbonyl ] amino-4-methyl-pentanoyl ] amino-3 ( - ) [ 3- ( 1-methyl-1H- indolyl ) ] propionyl ] amino-3- ( 2-pyridyl ) proprionic acid ] on rats in which NO synthase was blocked
Beck et al., Kidney Int 1995 : Endothelin-1 inhibits cytokine stimulated transcription of inducible nitric oxide synthase in glomerular mesangial cells
Edwards et al., Am J Obstet Gynecol 1996 (Body Weight...) : We postulated that long-term nitric oxide synthase inhibition with L-nitro-arginine methyl ester would induce sustained hypertension, a rise in plasma levels of endothelin-1 , and fetal growth restriction ... Long-term nitric oxide synthase blockade causes sustained hypertension, elevated levels of endothelin-1 , and fetal growth restriction
Hirahashi et al., Pharmacology 1996 : Endothelin-1 inhibits induction of nitric oxide synthase and GTP cyclohydrolase I in rat mesangial cells
Lin et al., Eur J Endocrinol 1998 : Role of nitric oxide synthase in release of endothelin from cultured human endometrial cells
Gude et al., Clin Exp Pharmacol Physiol 1998 : 2. Vasoconstriction responses to 5-hydroxytryptamine ( 5-HT ) were potentiated in the presence of endothelin-1 (ET-1) , the thromboxane A2-mimetic U46619 and a nitric oxide synthase inhibitor , N-nitro-L-arginine ( NOLA ), but not in the presence of angiotensin II